ArticleNature immunology2024
Specific CD4
Erratum issuedAbstract read
In one paragraph
Article in Nature immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 40 papers.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Fast, flexible analysis of differences in cellular composition with crumblr.Nature communications · 2026Article
- Review
- Infection control in the brain and the eye.Acta ophthalmologica · 2026Review
- Airway immune signatures of protection and disease progression in recent human tuberculosis household contacts.Nature immunology · 2026Article
- The host immune response to Mycobacterium tuberculosis determining protection or disease progression.Nature immunology · 2026Review
- Superior protection against tuberculosis using heterologous mRNA nanoadjuvant vaccines.NPJ vaccines · 2026Article
- Mycobacterium tuberculosis-Specific CFP-10/ESAT-6 CD4 and CD8 T-Cell Non-IFN-γ+ Responses Are Common in Young Kenyan Children Despite Low Reported Tuberculosis Exposure.The Journal of infectious diseases · 2026Article
- IFNγ blockade in Mycobacterium tuberculosis infected macaques alters the granuloma environment but not bacterial control.Nature communications · 2026Article
- Dynamics of IFN-γ, IL-2, and IL-6 during early tuberculosis treatment: significant longitudinal changes but limited value as standalone discriminators of treatment status.BMC microbiology · 2026Article
- Mycobacterium tuberculosis bacteriology and immunity necessitate a multi-pronged immune strategy for vaccination.NPJ vaccines · 2026Review
- Context-specific roles for IL-17 in tuberculosis.PLoS pathogens · 2026Review
- Rare variable M. tuberculosis antigens induce predominant Th17 responses in human infection.JCI insight · 2026Article
- A Deep Representation Learning Method for Quantitative Immune Defense Function Evaluation and Its Clinical Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Strong sustained type I IFN signaling acts cell intrinsically to impair IFNγ responses and cause tuberculosis susceptibility.bioRxiv : the preprint server for biology · 2026Article
- A co-evolutionary perspective on humans andeLife · 2026Review
- T cell-macrophage interactions in tuberculosis: What we've got here is failure to communicate.Journal of internal medicine · 2026Review
- Immunotherapy for tuberculosis: emerging modalities, cross-disciplinary innovations, and roadmaps for drug-resistant disease.Frontiers in immunology · 2026Review
- Prophylactic and post-exposure efficacy of a Pichinde virus vector-based tuberculosis vaccine.Frontiers in immunology · 2026Article
- AFrontiers in tuberculosis · 2026Article
- Review
Corrections and comments
- Erratum issued
Authors and funding
25 authors.
Meng Sun *Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-5753-2775
Jolie M Phan *Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-2512-868X
Nathan S Kieswetter *Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Huang HuangInstitute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA, USA.
Krystle K Q YuDepartment of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Malisa T SmithDepartment of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Yiran E LiuInstitute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA, USA.
Chuangqi WangDepartment of Immunology and Microbiology, University of Colorado, Anschutz Medicine Campus, Aurora, CO, USA.ORCID http://orcid.org/0000-0002-4779-2231
Sanjana GuptaInstitute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA, USA.
Gerlinde ObermoserHuman Immune Monitoring Center, Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA, USA.
Holden Terry MaeckerHuman Immune Monitoring Center, Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-0795-9946
Akshaya KrishnanHuman Immune Monitoring Center, Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA, USA.
Sundari SureshHuman Immune Monitoring Center, Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA, USA.
Neha GuptaInstitute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-6300-1671
Mary RieckHuman Immune Monitoring Center, Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA, USA.
Peter AcsHuman Immune Monitoring Center, Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA, USA.
Mustafa GhanizadaInstitute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-2774-2157
Shin-Heng ChiouDivision of Medical Oncology, Rutgers Cancer Institute of New Jersey, Department of Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA.
Purvesh KhatriInstitute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-4143-4708
W Henry BoomDepartment of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Thomas R HawnDepartment of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Catherine M SteinDepartment of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA.ORCID http://orcid.org/0000-0002-9763-5023
Harriet Mayanja-KizzaDepartment of Medicine, Makerere University School of Medicine, Kampala, Uganda.
Mark M Davis *Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA, USA. mmdavis@stanford.edu.ORCID http://orcid.org/0000-0001-6868-657X
Chetan Seshadri *Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA. seshadri@uw.edu.ORCID http://orcid.org/0000-0003-2783-7540
Funding
Using a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5MIMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB)75N93019C00071 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI FORTUNE, SARAH · 2019 to 2025
$57.3MThe effects of immune-age on immune-response and the molecular mechanisms which drive itP01AI153559 · NIAID · STANFORD UNIVERSITY · PI DAVIS, MARK MORRIS · 2021 to 2025
$17.8MResistance to MTB infection in HIV infected individuals in Uganda and S. AfricaR01AI124348 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BOOM, W. HENRY, HAWN, THOMAS R · 2016 to 2020
$11.3MThe Role of Lipid-specific T cells in Mediating Protection Against M. tuberculosisR01AI146072 · NIAID · UNIVERSITY OF WASHINGTON · PI CHETAN SESHADRI · 2020 to 2026
$6.0MNatural Resistance to Mycobacterium Tuberculosis InfectionU01AI115642 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BOOM, W. HENRY, MAYANJA-KIZZA, HARRIET · 2015 to 2019
$3.5MQualification of Assays to Measure Human T-cell Responses Against Mycobacterial Lipid AntigensR01AI125189 · NIAID · UNIVERSITY OF WASHINGTON · PI SESHADRI, CHETAN · 2016 to 2020
$3.1MPulmonary Innate Immunity & Resistance to Mycobacterium Tuberculosis InfectionK24AI137310 · NIAID · UNIVERSITY OF WASHINGTON · PI HAWN, THOMAS R · 2018 to 2022
$892kBill and Melinda Gates Foundation (Bill & Melinda Gates Foundation) OPP1109001Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation) OPP1113682Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation) OPP1151836NIAID NIH HHS 75N93019C00071NIAID NIH HHS K24 AI137310NIAID NIH HHS P01 AI153559NIAID NIH HHS R01 AI124348NIAID NIH HHS R01 AI125189NIAID NIH HHS R01 AI146072NIAID NIH HHS U01 AI115642NIAID NIH HHS U19 AI057229
Abstract
A subset of individuals exposed to Mycobacterium tuberculosis (Mtb) that we refer to as 'resisters' (RSTR) show evidence of IFN-γ
Indexed as
CD4-Positive T-LymphocytesMycobacterium tuberculosisTuberculosisAdolescentAdultAnimalsAntigens, BacterialFemaleHumansInterferon-gammaLatent TuberculosisMacaca mulattaMalePhenotypeSouth AfricaTh17 CellsAntigens, BacterialInterferon-gamma
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.